Last reviewed · How we verify

RANITIDINE HYDROCHLORIDE

FDA-approved approved Small molecule ✓ Verified May 2026 Quality 5/100

RANITIDINE HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 1983).

Ranitidine hydrochloride is a medication used to treat conditions such as dyspepsia and reflux oesophagitis. It is also being studied in clinical trials for other conditions including renal cell carcinoma and multiple myeloma.

At a glance

Generic nameRANITIDINE HYDROCHLORIDE
ModalitySmall molecule
PhaseFDA-approved
First approval1983

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RANITIDINE HYDROCHLORIDE

What is RANITIDINE HYDROCHLORIDE?

RANITIDINE HYDROCHLORIDE is a Small molecule drug.

When was RANITIDINE HYDROCHLORIDE approved?

RANITIDINE HYDROCHLORIDE was first approved on 1983.

What development phase is RANITIDINE HYDROCHLORIDE in?

RANITIDINE HYDROCHLORIDE is FDA-approved (marketed).

What are the side effects of RANITIDINE HYDROCHLORIDE?

Common side effects of RANITIDINE HYDROCHLORIDE include Headache, Constipation, Diarrhea, Nausea/Vomiting, Abdominal discomfort/pain. Serious adverse events: Hepatocellular, cholestatic, or mixed hepatitis, Hepatic failure, Aplastic anemia, Agranulocytosis.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing